
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of Your Number one BWM Vehicles - 2
Hunger and makeshift shelters persist in north Caribbean nearly 2 months after Hurricane Melissa - 3
Top 15 Style Creators Changing the Business - 4
Japan deploys the military to counter a surge in bear attacks - 5
NASA study shows how satellite 'light pollution' hinders space telescopes
IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
Email Promoting Instruments for Compelling Efforts
Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
The most effective method to Settle on Informed Conclusions about Senior Insuranc.
Medtronic has 'significant firepower' for multiple acquisitions, executives say
What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
$30K Disability Scam Implodes After Surf Trip in Mexico
Hot Electric Vehicles for 2023













